Premium
Is the determination of anti‐beta2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome?
Author(s) -
Hsieh Kety,
Knöbl Paul,
Rintelen Claudia,
Kyrle Paul A.,
Quehenberger Peter,
Bialonczyk Christine,
Partsch Hugo,
Lechner Klaus,
Pabinger Ingrid
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04595.x
Subject(s) - medicine , interquartile range , lupus anticoagulant , antibody , gastroenterology , antiphospholipid syndrome , thrombosis , venous thrombosis , immunology
Summary. Anti‐beta2‐glycoprotein I (beta2GPI) antibodies are frequently found in patients with lupus anticoagulant (LA). To investigate the prevalence of antibeta2GPI antibodies and their clinical impact in patients with a history of venous thromboembolism (VTE) without LA/anticardiolipin antibodies (ACA), we studied 503 patients [128 (36·2%) men, median age 41 years (interquartile range, IQR 28–54 years)] with previous thrombosis. A group of 113 individuals without VTE [43 (38·1%) men, age 46·7 years (IQR 38–52 years)] served as a control group. Among 418 patients without LA/ACA, anti‐beta2GPI‐IgG levels were elevated in seven (1·7%), ‐IgM in 15 (3·6%) and ‐IgA in 14 (3·3%) cases; in 58 patients with ACA, anti‐beta2GPI‐IgG levels were elevated in two (3·4%), six (10·3%) and three (5·2%), and in 27 with LA, they were elevated in 18 (66·7%), 19 (70·4%) and 10 (37%) respectively. Thus, the prevalence of elevated anti‐beta2GPI antibodies was not increased in patients without LA/ACA but was strongly associated with LA. Patients without ACA/LA who had a recurrent event did not have higher prevalence of elevated anti‐beta2GPI‐IgG, ‐IgM or ‐IgA antibodies than those without a recurrent event. Thus, elevated antibeta2GPI antibodies are not likely to be a predictor of recurrent events in patients without LA. We conclude that determination of anti‐beta2GPI antibodies does not improve the clinical management of patients with a history of VTE without LA/ACA.